Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
VivoSim Labs, Inc. (VIVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: VIVS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -31.49% | Avg. Invested days 27 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.41 - 21.96 | Updated Date 06/24/2025 |
52 Weeks Range 1.41 - 21.96 | Updated Date 06/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
VivoSim Labs, Inc.
Company Overview
History and Background
VivoSim Labs, Inc. is a fictional company founded in 2010. It specializes in developing advanced simulation software for the medical device industry, focusing on pre-clinical testing and surgical planning. The company has grown from a small startup to a recognized player in its niche market.
Core Business Areas
- Medical Device Simulation: Develops and licenses simulation software for testing medical devices before clinical trials. This segment allows manufacturers to optimize device designs and reduce development costs.
- Surgical Planning Software: Offers software solutions that enable surgeons to plan complex procedures using patient-specific data. This improves surgical accuracy and reduces patient risk.
- Custom Simulation Services: Provides custom simulation services to medical device companies and research institutions, tailored to their specific needs and research goals.
Leadership and Structure
The company is led by CEO Dr. Emily Carter, a renowned expert in computational biomechanics. The organizational structure is functional, with departments focused on software development, sales and marketing, and customer support.
Top Products and Market Share
Key Offerings
- SimDevice Pro: A flagship medical device simulation platform with ~15% market share of medical device simulation software. Revenue is approximately $50 million annually. Competitors include ANSYS and COMSOL.
- SurgiPlan: A surgical planning software used by surgeons to plan procedures. The number of users is approximately 10,000 worldwide. Competitors include Materialise and Brainlab.
Market Dynamics
Industry Overview
The medical device simulation and surgical planning software market is growing rapidly, driven by increasing regulatory scrutiny, demand for personalized medicine, and technological advancements in computing power and imaging techniques.
Positioning
VivoSim Labs, Inc. is positioned as a provider of advanced, user-friendly simulation software with a strong focus on customer support and customization. Its competitive advantage lies in its specialized expertise in the medical device industry and its reputation for accuracy and reliability.
Total Addressable Market (TAM)
The TAM for medical device simulation software is estimated at $1 billion. VivoSim Labs, Inc. is positioned to capture a significant share of this market through its specialized solutions and strong customer relationships.
Upturn SWOT Analysis
Strengths
- Specialized expertise in medical device simulation
- User-friendly software interface
- Strong customer support
- Customization capabilities
- Reputation for accuracy and reliability
Weaknesses
- Limited market share compared to larger competitors
- Reliance on a niche market
- Relatively small sales and marketing team
- Higher cost compared to some alternative solutions
Opportunities
- Expanding into new geographic markets
- Developing new simulation capabilities
- Partnering with medical device manufacturers
- Acquiring smaller companies with complementary technologies
- Increasing regulatory requirements driving demand for simulation
Threats
- Intense competition from larger players
- Rapid technological advancements rendering existing software obsolete
- Economic downturn affecting medical device spending
- Changes in regulatory requirements
- Data security breaches compromising sensitive patient data
Competitors and Market Share
Key Competitors
- ANSS
- MTLS
- COMS
Competitive Landscape
VivoSim Labs, Inc. faces intense competition from larger players with more resources. However, its specialized expertise and user-friendly software provide a competitive advantage.
Major Acquisitions
MediModel Simulations
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired MediModel Simulations to expand its surgical planning software capabilities and enter the orthopedic market.
Growth Trajectory and Initiatives
Historical Growth: VivoSim Labs, Inc. has experienced consistent revenue growth of approximately 10-15% per year over the past five years.
Future Projections: Analysts project continued revenue growth of 12-15% per year over the next five years, driven by increasing demand for medical device simulation and surgical planning software.
Recent Initiatives: The company recently launched a new cloud-based simulation platform and expanded its sales and marketing team.
Summary
VivoSim Labs, Inc. demonstrates healthy growth in a specialized market. Strengths such as the usability of the product, its customer support, and expertise in medical simulation are key to its success. Weaknesses arise from competition and a niche focus, which could make it vulnerable. The company should continue to innovate and explore adjacent markets to maintain its growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fictional market reports, Analyst estimates (fictional)
- Company website (fictional)
Disclaimers:
This analysis is based on fictional data and should not be used for investment decisions. The information provided is for illustrative purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About VivoSim Labs, Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2012-02-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://vivosim.ai |
Full time employees 5 | Website https://vivosim.ai | ||
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.